Opiates and Other Analgesics

  • Marc A. Schuckit
Part of the Critical Issues in Psychiatry book series (CIPS)


This chapter is concerned with those pain-killing drugs (analgesics) that are most likely to be misused, ranging from propoxyphene (Darvon) through the synthetic, opiatelike drugs to the major opiates, including morphine and heroin. The generalizations made here apply to almost all prescription painkillers, with the exception of the newer prescription antiinflammatory medications. The material might also be relevant to the newer opiate-type drugs, including the mixed agonist¡ªantagonist butorphanol (Stadol or Borphanol), which is similar to buprenorphene and nalbuphene, as well as fentanyl (Sublimaze). Most of these newer medications have not yet met the test of time to determine their actual propensity to develop adverse reactions, including addiction. 1,2


Alcohol Abuse England Journal Methadone Maintenance Opiate Receptor Opiate Withdrawal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Vandam, L. D. Butorphanol. New England Journal of Medicine 302: 381–384, 1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Hayes, J. R. Gentanyl. Newsletter: California Society for the Treatment of Alcoholism and Other Drug Dependencies 8: 3–5, 1981.Google Scholar
  3. 3.
    Inturrisi, C. E., Max, M. B., Foley, K. M., The pharmacokinetics of heroin in patients with chronic pain. New England Journal of Medicine 310: 1213–1217, 1984.PubMedCrossRefGoogle Scholar
  4. 4.
    Berridge, V. Opium and the historical perspective. Lancet 2: 78–80, 1977.PubMedCrossRefGoogle Scholar
  5. 5.
    Musto, D. F. The American Disease: Origins of Narcotic Control. New Haven, Connecticut: Yale University Press, 1973.Google Scholar
  6. 6.
    Stimmel, B. Heroin Dependency: Medical, Economic, and Social Aspects. New York: Stratton Intercontinental Medical Book Corp., 1975.Google Scholar
  7. 7.
    Jaffe, J. H. Drug addiction and drug abuse. In A. G. Gilman, L. S. Goodman, T. W. Rall, und F. Murad (Eds.), The Pharmacological Basis of Therapeutics ( 7th ed. ). New York: Macmillan, 1985, pp. 532–581.Google Scholar
  8. 8.
    Woods, J. H., und Winger, G. Opioids, receptors, and abuse liability. In H. Y. Meltzer (Ed.), Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987, pp. 1555–1564.Google Scholar
  9. 9.
    Jaffe, J. H., und Martin, W. R. Opioid analgesics and antagonists. In A. G. Gilman, L. S. Goodman, T. W. Rall, und F. Murad (Eds.), The Pharmacological Basis of Therapeutics ( 7th ed. ), New York: Macmillan, 1985, pp. 491–531.Google Scholar
  10. 10.
    Marshall, B. E., und Wollman, H. General anesthetics. In A. G. Gilman, L. S. Goodman, T. W. Rall, und F. Murad (Eds.), The Pharmacological Basis of Therapeutics ( 7th ed. ). New York: Macmillan, 1985, pp. 276–301.Google Scholar
  11. 11.
    Koob, G. F., und Bloom, F. E. Behavioral effects of opioid peptides. British Medical Bulletin 39: 89–94, 1983.PubMedGoogle Scholar
  12. 12.
    Cohen, M. R., Cohen, R. M., Pickar, D., behavioural effects after high dose naloxone administration to normal volunteers. Lancet 2:1110, 1981.Google Scholar
  13. 13.
    Bloom, F., Segal, D., Ling, N., et al. Endorphins: Profound behavioral effects in rats suggest new etiological factors in mental illness. Science 194: 630–632, 1976.PubMedCrossRefGoogle Scholar
  14. 14.
    Mathiasen, J. R., Raffa, R. B., und Vaught, J. L. Mice: Differential sensitivity in the tail flick test to centrally administered Mu-and Delta-opioid receptor agonists. Life Sciences 40:1989–1994, 1987.Google Scholar
  15. 15.
    Woods, J. H., und Winger, G. Behavioral characterization of opioid mixed agonist-antagonists. Paper presented at the Committee on Problems in Drug Dependence Annual Meeting, Philadelphia, June 16, 1987.Google Scholar
  16. 16.
    Pfeiffer, A., Brantl, V., Herz, A., und Emrich, H. M. Psychotomimesis mediated by K opiate receptors. Science 233: 774–776, 1986.PubMedCrossRefGoogle Scholar
  17. 17.
    Kleber, H. D. Trexan: A Pharmacologic Adjunct for the Detoxified Opioid Addict. Wilmington, Delaware: E. I. du Pont de Nemours, 1984.Google Scholar
  18. 18.
    Bozarth, M. A., und Wise, R. A. Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 224: 514–517, 1984.CrossRefGoogle Scholar
  19. 19.
    Bums, R. S., LeWitt, P. A., Ebert, M. H., et al. The clinical syndrome of striatal dopamine deficiency. New England Journal of Medicine 312: 1418–1421, 1985.CrossRefGoogle Scholar
  20. 20.
    Langston, J., Ballard, P., Tatrud, J., und Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 9789–9790, 1983.CrossRefGoogle Scholar
  21. 21.
    Stimmel, B. The socioeconomics of heroin dependency. New England Journal of Medicine 287: 1275–1280, 1972.PubMedCrossRefGoogle Scholar
  22. 22.
    Zinberg, N. E., und Jacobson, R. C. The natural history of “chipping.” American Journal of Psychiatry 133: 37–40, 1976.PubMedGoogle Scholar
  23. 23.
    Caplovitz, D. The Working Addict. New York: The Graduate School and the University Center of the City University of New York, 1976.Google Scholar
  24. 24.
    Dess, W. J., und Cole, F. C. The medically evacuated Viet-Nam narcotic abuser: A follow-up rehabilitative study. Bulletin on Narcotics 24:55–65, 1977.Google Scholar
  25. 25.
    Robins, L. N., Heizer, J. E., und Davis, D. H. Narcotic use in Southeast Asia and afterward. Archives of General Psychiatry 32: 955–961, 1975.PubMedCrossRefGoogle Scholar
  26. 26.
    Wechsler, H., und Rohman, M. E. Patterns of drug use among New England college students. American Journal of Drug and Alcohol Abuse 8: 27–37, 1981.PubMedCrossRefGoogle Scholar
  27. 27.
    Messeri, P. A., und Brunswick, A. F. Heroin availability and aggregate levels of use: Secular trends in an urban black cohort. American Journal of Drug and Alcohol Abuse 13:109–133, 1987.Google Scholar
  28. 28.
    Des Jarlais, D. C., und Uppal, G. S. Heroin activity in New York City, 1970–1978. American Journal of Drug and Alcohol Abuse 7: 335–346, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Ruttenbar, A. J., und Luke, J. L. Heroin-related deaths: New epidemiologic insights. Science 226: 14–20, 1984.CrossRefGoogle Scholar
  30. 30.
    Hartnoll, R., Lewis, R., Mitcheson, M., und Bryer, S. Estimating the prevalence of opioid dependence. Lancet 1:203–205, 1985.Google Scholar
  31. 31.
    Kandel, D. B., und Logan, J. A. Patterns of drug use from adolescence to young adulthood: Periods of risk for initiation, continued use, and discontinuation. American Journal of Public Health 74: 660–666, 1984.PubMedCrossRefGoogle Scholar
  32. 32.
    Editorial: Alcohol and politics. Lancet 1:1358–1359, 1987.Google Scholar
  33. 33.
    Smart, R. G., und Adlaf, E. M. Pattems of drug use among adolescents: The past decade. Social Science Medicine 23: 717–719, 1986.CrossRefGoogle Scholar
  34. 34.
    Editorial: National survey finds continuing decline in use of illicit drugs by high school seniors. Hospital and Community Psychiatry 36: 1011, 1985.Google Scholar
  35. 35.
    Smart, R. G., Goodstadt, M. S., Adlaf, E. M., Trends in the prevalence of alcohol and other drug use among Ontario students: 1977–1983. Canadian Journal of Public Health 76: 157–161, 1985.Google Scholar
  36. 36.
    Nicholi, A. M. The nontherapeutic use of psychoactive drugs. New England Journal of Medicine 308: 925–933, 1983.PubMedCrossRefGoogle Scholar
  37. 37.
    Rounsaville, B. J., und Kleber, H. D. Untreated opiate addicts. Archives of General Psychiatry 42: 1072–1077, 1985.PubMedCrossRefGoogle Scholar
  38. 38.
    Halikas, J. A., Darvish, H. S., und Rimmer, J. D. The black addict. 1. Methodology, chronology of addiction, and overview of the population. American Journal of Drug and Alcohol Abuse 3: 529-543, 1976.Google Scholar
  39. 39.
    Maddux, J., und Desmond, D. P. Heroin addicts and nonaddicted brothers. American Journal of Drug and Alcohol Abuse 1: 237–248, 1984.Google Scholar
  40. 40.
    Croughan, J. L., Miller, J. P., Waggelin, D., Psychiatric illness in male and female narcotic addicts. Journal of Psychiatry 43:225–228, 1982.Google Scholar
  41. 41.
    Langenauer, B. J., und Bowden, C. L. A follow-up study of narcotic addicts in the NARA program. American Journal of Psychiatry 128: 73–78, 1971.Google Scholar
  42. 42.
    O’Brien, C. P., Woody, G. E., und McLellan, A. T. Long-term consequences of opiate dependence. New England Journal of Medicine 304:1098–1099, 1981.Google Scholar
  43. 43.
    Vaillant, G. E. A 20-year follow-up of New York narcotic addicts. Archives of General Psychiatry 29: 237–241, 1973.PubMedCrossRefGoogle Scholar
  44. 44.
    Snow, M. Maturing out of narcotic addiction in New York City. International Journal of the Addictions 8: 921–938, 1973.PubMedGoogle Scholar
  45. 45.
    Kosten, T. R., Rounsaville, B. J., und Kleber, H. D. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Archives of General Psychiatry 43: 733738, 1986.Google Scholar
  46. 46.
    Kreek, M. J. Health consequences associated with methadone. In J. Cooper, und F. Altman (Eds.), NIDA Research Monograph Series, Department of Health and Human Services Publication (ADM) 83–1281. Washington, D.C.: U.S. Government Printing Office, 1983, pp. 456–482.Google Scholar
  47. 47.
    Winick, C. The life cycle of the narcotic addict and of addiction. Bulletin on Narcotics 26: 1–11, 1964.Google Scholar
  48. 48.
    Kandel, D. B. Longitudinal Research on Drug Use. New York: Halstead Press, 1978.Google Scholar
  49. 49.
    Simpson, D. D., und Lloyd, M. R. Alcohol use following treatment for drug addiction. Journal of Studies on Alcohol 42: 323–335, 1981.PubMedGoogle Scholar
  50. 50.
    Croughan, J. L., Miller, J. P., Whitman, B. Y., und Schober, J. G. Alcoholism and alcohol dependence in narcotic addicts: A prospective study with a five-year follow-up. American Journal of Drug and Alcohol Abuse 8: 85–94, 1981.PubMedCrossRefGoogle Scholar
  51. 51.
    McGlothlin, W. H., und Anglin, M. D. Shutting off methadone: Costs and benefits. Archives of General Psychiatry 38: 885–892, 1981.PubMedCrossRefGoogle Scholar
  52. 52.
    Lass, H. Most chronic pain patients misuse drugs, study shows. Hospital Tribune World Service 6: 2, 1976.Google Scholar
  53. 53.
    McAuliffe, W. E., Rohman, M., Santangelo, S., et al. Psychoactive drug use among practicing physicians and medical students. New England Journal of Medicine 315: 805–810, 1986.PubMedCrossRefGoogle Scholar
  54. 54.
    Maddux, J. F., Hoppe, S. K., und Costello, R. M. Psychoactive substance use among medical students. American Journal of Psychiatry 143:187–191, 1986.Google Scholar
  55. 55.
    Jones, R. E. A study of 100 physician psychiatric inpatients. American Journal of Psychiatry 134: 1119–1122, 1977.PubMedGoogle Scholar
  56. 56.
    Chotkowski, L. A. Clubbing of the fingers in heroin addiction. New England Journal of Medicine 311: 262, 1984.PubMedGoogle Scholar
  57. 57.
    Siegel, S., Hinson, R. E., Krank, M. D., und McCully, J. Heroin “overdose” death: Contribution of drug-associated environmental cues. Science 216: 436–437, 1982.PubMedCrossRefGoogle Scholar
  58. 58.
    Greene, M. H., und DuPont, R. L. The treatment of acute heroin toxicity. In P. G. Bourne (Ed.). A Treatment Manual for Acute Drug Abuse Emergencies. Washington, D.C.: U.S. Government Printing Office, 1974, pp. 11–16.Google Scholar
  59. 59.
    Dimijian, G. G. Differential diagnosis of emergency drug reactions. In P. G. Boume (Ed.). A Treatment Manual for Acute Drug Abuse Emergencies. Washington, D.C.: U.S. Government Printing Office, 1974, pp. 1–7.Google Scholar
  60. 60.
    Kleber, H. D. The treatment of acute heroin toxicity. In P. G. Bourne (Ed.), A Treatment Manual for Acute Drug Abuse Emergencies. Washington, D.C.: U.S. Government Printing Office, 1974, pp. 17–21.Google Scholar
  61. 61.
    Oppenheimer, E., Stimson, G. V., und Thorley, A. Seven-year follow-up of heroin addicts: Abstinence and continued use compared. British Medical Journa 12: 627–630, 1979.CrossRefGoogle Scholar
  62. 62.
    McLellan, A. T., Woody, G. E., und O’Brien, C. P. Development of psychiatric illness in drug abusers. New England Journal of Medicine 301: 1310–1314, 1979.CrossRefGoogle Scholar
  63. 63.
    Kosten, T. R., und Rounsaville, B. J. Suicidality among opioid addicts. American Journal of Drug and Alcohol Abuse 14: 357–369, 1988.PubMedCrossRefGoogle Scholar
  64. 64.
    Rousaville, B. J., Weissman, M. M., Crits-Christoph, K., Diagnosis and symptoms of depression in opiate addicts. Archives of General Psychiatry 39: 151–156, 1982.CrossRefGoogle Scholar
  65. 65.
    Donis, W., und Senay, E. C. Depression, demographics, and drug abuse. American Journal of Psychiatry /37: 699–704, 1980.Google Scholar
  66. 66.
    Eisendrath, S. J., Goldman, B., Dougland, J, Meperidine-induced delirium. American Journal of Psychiatry 144: 1062–1065, 1987.PubMedGoogle Scholar
  67. 67.
    Siegel, S. Evidence from rats that morphine tolerance is a learned response. Journal of Comparative Physiology and Psychology 89: 498–506, 1975.CrossRefGoogle Scholar
  68. 68.
    Gossop, M., Green, L., Phillips, G., und Bradley, B. What happens to opiate addicts immediately after treatment: A prospective follow-up study. British Medical Journal 294:1377–1380. 1987.Google Scholar
  69. 69.
    Sorenson, J. L., Hargreaves, W. A., und Weinberg, J. A. Withdrawal from heroin in three or six weeks. Archives of General Psychiatry 39: 167–171, 1982.CrossRefGoogle Scholar
  70. 70.
    Shapira, J. Drug Abuse: A Guide for the Clinician. New York: American Elsevier, 1975.Google Scholar
  71. 71.
    Wen, H. L., Ho, W. K. K., und Wen, P. Y. C. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. European Journal of Pharmacology 100: 155–162, 1984.PubMedCrossRefGoogle Scholar
  72. 72.
    Tennant, F. S., und Uelman, G. F. Prescribing narcotics to habitual and addicted narcotic users: Medical and legal guidelines in California and some other Western states (medicine and the law). Western Journal of Medicine 133:539–545, 1980.Google Scholar
  73. 73.
    Tennant, F. S., Russell, B. A., Casas, S. K., Heroin detoxification: A comparison of propoxyphene and methadone. Journal of the American Medical Association 232: 1019–1022, 1975.PubMedCrossRefGoogle Scholar
  74. 74.
    Jasinski, D. R., Pevnick, J. S., Clark, S. C., und Griffith, J. D. Therapeutic usefulness of propoxyphene napsylate in narcotic addiction. Archives of General Psychiatry 34: 227–233, 1977.PubMedCrossRefGoogle Scholar
  75. 75.
    Ives, T. J., und Stults, C. C. Short-course diphenoxylate hydrochloride for treatment of methadone withdrawal symptoms. British Journal of Psychiatry 143: 513–514, 1983.PubMedCrossRefGoogle Scholar
  76. 76.
    Franz, D. N., Hare, B. D., und McCloskey, K. L. Spinal sympathetic neurons: Possible sites of opiate-withdrawal suppression by clonidine. Science 215:1643–1645, 1982.Google Scholar
  77. 77.
    Charney, D. S., Riordan, C. E., Kleber, H. D., A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. Archives of General Psychiatry 39:1327–1332, 1982.Google Scholar
  78. 78.
    Chamey, D. S., Heninger, G. R., und Kleber, H. D. The combined use of clonidine and naltrexone as a rapid, safe, and effective treatment of abrupt withdrawal from methadone. American Journal of Psychiatry 143: 831–837, 1986.Google Scholar
  79. 79.
    Jasinski, D. R., Johnson, R. E., und Kocher, T. R. Clonidine in morphine withdrawal. Archives of General Psychiatry 42: 1063–1066, 1985.PubMedCrossRefGoogle Scholar
  80. 80.
    Schuckit, M. Clonidine and the treatment of withdrawal. Drug Abuse and Alcoholism Newsletter 17 (3): 1–4, 1988.Google Scholar
  81. 81.
    Charney, D. S., Sternberg, D. E., Kleber, H. D., et al. The clinical use of clonidine in abrupt withdrawal from methadone. Archives of General Psychiatry 38: 1273–1277, 1981.PubMedCrossRefGoogle Scholar
  82. 82.
    Kleber, H. D., Topazian, M., Gaspari, J., Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. American Journal of Drug and Alcohol Abuse 13:1–17, 1987.Google Scholar
  83. 83.
    Clark, H. W., und Longmuir, N. Clonidine transdermal patches: A recovery oriented treatment of opiate withdrawal. Newsletter: California Society for the Treatment of Alcoholism and Other Drug Dependencies 13, 1986.Google Scholar
  84. 84.
    Schubert, H., Fleischhacker, W. W., Meise, U., und Theohar, C. Preliminary results of guanfacine treatment of acute opiate withdrawal. American Journal of Psychiatry 141:1271–1273, 1984.Google Scholar
  85. 85.
    Jasinski, D. R., Johnson, R. E., und Makhxoumi, H. E.ficiency of clonidine in morphine withdrawal. Paper presented at the 20th Annual American College of Neuropsychopharmacology meeting in San Diego, December 16–18, 1981.Google Scholar
  86. 86.
    Wen, G., und Keith, L. Drug addiction in pregnancy. In J. J. Sciarra (Ed.), Gynecology and Obstetrics. Philadelphia: Harper and Row, 1983, pp. 119–127.Google Scholar
  87. 87.
    Clement-Jones, V., Tomlin, S., Rees, L. H., et al. Increased 3-endorphin but not metenkephalin levels in human cerebrospinal fluid after acupuncture for recurrent pain. Lancet 2: 946–948, 1980.PubMedCrossRefGoogle Scholar
  88. 88.
    Sheffet, A., Quinones, M., Levenhar, M. A., An evaluation of detoxification as an initial step in the treatment of heroin addiction. American Journal of Psychiatry 133: 337–340, 1976.PubMedGoogle Scholar
  89. 89.
    Finnegan, L. P. Neonatal abstinence syndrome: Assessment and pharamcotherapy. In F. F. Rubaltelli und B. Granati (Eds.), Neonatal Therapy: An Update. New York: Elsevier, 1986, pp. 122–146.Google Scholar
  90. 90.
    Fitzsimmons, J., Tunis, S., Webster, D., et al. Pregnancy in a drug-abusing population. American Journal of Drug and Alcohol Abuse 12: 247–255, 1986.PubMedCrossRefGoogle Scholar
  91. 91.
    Green, M., und Suffet, F. The neonatal narcotic withdrawal index: A device for the improvement of care in the abstinence syndrome. American Journal of Drug and Alcohol Abuse 8: 203–213, 1981.PubMedCrossRefGoogle Scholar
  92. 92.
    Hoder, E. L., Leckman, J. F., Ehrenkranz, R., Clonidine in neonatal narcotic-abstinence syndrome. New England Journal of Medicine 305:1284, 1981.Google Scholar
  93. 93.
    Strass, M. E., Andresko, M., Stryker, J. C., et al. Relationship of neonatal withdrawal to maternal methadone dose. American Journal of Drug and Alcohol Abuse 3: 339–345, 1976.CrossRefGoogle Scholar
  94. 94.
    Friedland, G. H., und Klein, R. S.: Transmission of the human immunodeficiency virus. New England Journal of Medicine 317:1125–1135, 1987.Google Scholar
  95. 95.
    Ancelle-Park, R., Brunet, J. B., und Downs, A. M. AIDS and drug addicts in Europe. Lancet 2: 626–627, 1987.PubMedCrossRefGoogle Scholar
  96. 96.
    Lettau, L. A., McCarthy, J. G., und Smith, M. J. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parental drug abusers and their contacts. New England Journal of Medicine 317:1256–1262, 1987.Google Scholar
  97. 97.
    Oliver, R. M. Bronchospasm and heroin inhalation. Lancet 1: 915, 1986.PubMedCrossRefGoogle Scholar
  98. 98.
    Rounsaville, B., Kosten, T., Weissman, M., und Kleber, H. Prognostic significance of psychopathology in treated opiate addicts. Archives of General Psychiatry 43: 739–745, 1986.PubMedCrossRefGoogle Scholar
  99. 99.
    Wolters, E., Stam, F. C., Lousberg, R. J., Leucoencephalopathy after inhaling “heroin” pyrolysate. Lancet 2:1233–1238, 1982.Google Scholar
  100. 100.
    Mendelson, J. H., Mendelson, J. E., und Patch, V. D. Plasma testosterone levels in heroin addiction and during methadone maintenance. Journal of Pharmacology and Experimental Therapeutics 192: 211–217, 1975.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Marc A. Schuckit
    • 1
  1. 1.San Diego School of Medicine, Veterans Administration HospitalUniversity of CaliforniaSan DiegoUSA

Personalised recommendations